Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 09 - 16 save search
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy
Published: 2021-09-16 (Crawled : 13:00) - biospace.com/
RVNC | $3.665 0.69% 0.68% 1.6M
|
Health Technology
|
| O: -0.83%
H: 1.06%
C: 0.72%
phase 3 trial
5 Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Published: 2021-09-16 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.23%
H: 0.31%
C: -1.02%
media renal phase 3 trial cell carcinoma nivolumab
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
cancer phase 3 breast cancer als
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
Published: 2021-09-16 (Crawled : 11:20) - biospace.com/
AXSM | $73.055 2.75% 2.68% 700K
|
Health Technology
|
| O: -0.32%
H: 6.3%
C: 3.26%
narcolepsy phase 3 trial
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
Published: 2021-09-16 (Crawled : 07:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -1.18%
H: 6.27%
C: 6.27%
phase 1 phase 3 phase 2
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.